Editorial
Interferon-α: A new target for therapy in systemic lupus erythematosus?
Mary K. Crow,
Corresponding Author
Mary K. Crow
The Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, New York
Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021Search for more papers by this authorMary K. Crow,
Corresponding Author
Mary K. Crow
The Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, New York
Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021Search for more papers by this author
REFERENCES
- 1 Blomberg S, Eloranta M-L, Magnusson M, Alm GV, Rönnblom L. Expression of the markers BDCA-2 and BDCA-4 and production of interferon-α by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Rheum 2003; 48: 2524–32.
- 2 Issacs A. Interferon. Adv Virus Res 1963; 10: 1–38.
- 3 Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979; 301: 5–8.
- 4 Martal JL, Chene NM, Huynh LP, L'Haridon RM, Reinaud PB, Guillomot MW, et al. IFN-tau: A novel subtype I IFN1. Structural characteristics, non-ubiquitous expression, structure-function relationships, a pregnancy hormonal embryonic signal and cross-species therapeutic potentialities. Biochimie 1998; 80: 755–77.
- 5 Preble OT, Black RJ, Friedman RM, Klippel JH, Vilcek J. Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science 1982; 216: 429–31.
- 6 Yee AMF, Yip YK, Fischer HD, Buyon JP. Serum activity that confers acid lability to α-interferon in systemic lupus erythematosus: its association with disease activity and its independence from circulating α-interferon. Arthritis Rheum 1990; 33: 563–8.
- 7 Rich SA. Human lupus inclusions and interferon. Science 1981; 213: 772–5.
- 8 Rönnblom LE, Alm GV, Öberg KE. Possible induction of systemic lupus erythematosus by interferon-α treatment in a patient with a malignant carcinoid tumour. J Intern Med 1990; 227: 207–10.
- 9 Svensson H, Johannisson A, Nikkila T, Alm GV, Cederblad B. The cell surface phenotype of human natural interferon-α producing cells as determined by flow cytometry. Scand J Immunol 1996; 44: 164–72.
- 10 Vallin H, Blomberg S, Alm GV, Cederblad B, Rönnblom L. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-α) production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol 1999; 115: 196–202.
- 11 Vallin H, Perers A, Alm GV, Rönnblom L. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-α inducer in systemic lupus erythematosus. J Immunol 1999; 163: 6306–13.
- 12 Båve U, Alm GV, Rönnblom L. The combination of apoptotic U937 cells and lupus IgG is a potent IFN-α inducer. J Immunol 2000; 165: 3519–26.
- 13 Båve U, Vallin H, Alm GV, Rönnblom L. Activation of natural interferon-α producing cells by apoptotic U937 cells combined with lupus IgG and its regulation by cytokines. J Autoimmun 2001; 17: 71–80.
- 14 Magnusson M, Magnusson S, Vallin H, Rönnblom L, Alm GV. Importance of CpG dinucleotides in activation of natural IFN-alpha-producing cells by a lupus-related oligodeoxynucleotide. Scand J Immunol 2001; 54: 543–50.
- 15 Batteux F, Palmer P, Daeron M, Weill B, Lebon P. FcgammaRII (CD32)-dependent induction of interferon-α by serum from patients with lupus erythematosus. Eur Cytokine Netw 1999; 10: 509–14.
- 16 Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999; 284: 1835–7.
- 17 Rönnblom L, Alm GV. A pivotal role for the natural interferon α-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med 2001; 194: F59–63.
- 18 Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000; 9: 664–71.
- 19 Bell DA, Morrison B, VandenBygaart P. Immunogenic DNA-related factors: nucleosomes spontaneously released from normal murine lymphoid cells stimulate proliferation and immunoglobulin synthesis of normal mouse lymphocytes. J Clin Invest 1990; 85: 1487–96.
- 20 Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416: 603–7.
- 21 Scheinecker C, Zwölfer B, Köller M, Männer G, Smolen JS. Alterations of dendritic cells in systemic lupus erythematosus: phenotypic and functional deficiencies. Arthritis Rheum 2001; 44: 856–65.
- 22 Blomberg S, Eloranta M-L, Cederblad B, Nordlin K, Alm GV, Rönnblom L. Presence of cutaneous interferon-α producing cells in patients with systemic lupus erythematosus. Lupus 2001; 10: 484–90.
- 23 Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon-α/β-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001; 159: 237–43.
- 24 Dzionek A, Sohma Y, Nagafune J, Cella M, Colonna M, Facchetti F, et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferonα/β induction. J Exp Med 2001; 194: 1823–34.
- 25 Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science 2001; 294: 1540–3.
- 26 Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003; 100: 2610–5.
- 27 Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711–23.
- 28 Crow MK, George S, Paget SA, Ly N, Woodward R, Fry K, et al. Expression of an interferon-alpha gene program in SLE [abstract]. Arthritis Rheum 2002; 46 Suppl 9: S281.
- 29 Preble OT, Rothko K, Klippel JH, Friedman RM, Johnston MI. Interferon-induced 2′-5′ adenylate synthetase in vivo and interferon production in vitro by lymphocytes from systemic lupus erythematosus patients with and without circulating interferon. J Exp Med 1983; 157: 2140–6.
- 30 Rozzo SJ, Allard JD, Choubey D, Vyse TJ, Izui S, Peltz G, et al. Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus. Immunity 2001; 15: 435–43.
- 31 Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH, et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003; 197: 777–88.
- 32 Crow MK. Studies of autologous T cell activation in the Kunkel laboratory. Lupus 2003; 12: 163–9.
- 33 Chernysheva AD, Kirou KA, Crow MK. T cell proliferation induced by autologous non-T cells is a response to apoptotic cells processed by dendritic cells. J Immunol 2002; 169: 1241–50.
- 34 Pisetsky DS, Wenk KS, Reich CF III. The role of CpG sequences in the induction of anti-DNA antibodies. Clin Immunol 2001; 100: 157–63.
- 35 Luft T, Pang KC, Thomas E, Hertzog P, Hart DN, Trapani J, et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 1998; 161: 1947–53.
- 36 Paquette RL, Hsu NC, Kiertscher SM, Park AN, Tran L, Roth MD, et al. Interferon-α and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol 1998; 64: 358–67.
- 37 Aman MJ, Tretter T, Eisenbeis I, Bug G, Decker T, Aulitzky WE, et al. Interferon-alpha stimulates production of interleukin-10 in activated CD4+ T cells and monocytes. Blood 1996; 87: 4731–6.
- 38 Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli G, Tough D. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001; 14: 461–70.
- 39 Kirou KA, Vakkalanka RK, Butler MJ, Crow MK. Induction of Fas ligand-mediated apoptosis by interferon-α. Clin Immunol 2000; 95: 218–26.
- 40 Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 1994; 152: 3685–92.
- 41 Georgescu L, Vakkalanka RK, Elkon KB, Crow MK. Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand. J Clin Invest 1997; 100: 2622–33.
- 42 Chuntharapai A, Lai J, Huang X, Gibbs V, Kim KJ, Presta LG, et al. Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: a candidate therapeutic for IDDM and SLE. Cytokine 2001; 15: 250–60.
